Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 578,889 | $367,148,770 | +16% | 0.33% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 553,800 | $351,236,574 | 0.79% | |
| 3. | Squarepoint Ops LLC Maxime Fortin (Cio) | 284,003 | $180,123,223 | +12% | 0.22% |
| 4. | AQR Capital Management Cliff Asness | 235,950 | $148,664,871 | +14% | 0.15% |
| 5. | 228,000 | $144,604,440 | +36% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $844.61 | 1,000 | $844,610.00 | 12,931 | 2024-11-01 | Filing | |
| $1,059.28 | 2 | $2,118.56 | 17,582 | 2024-10-01 | Filing | |
| $1,057.38 | 2 | $2,114.76 | 17,584 | 2024-10-01 | Filing | |
| $1,056.68 | 3 | $3,170.04 | 17,586 | 2024-10-01 | Filing | |
| $1,054.90 | 3 | $3,164.70 | 17,589 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 423,325 | $222,245,625 | 0.33% | |
| 2. | 228,297 | $119,855,925 | 0.13% | |
| 3. | 67,300 | $35,332,500 | 3.75% | |
| 4. | 41,588 | $21,833,544 | 1.36% | |
| 5. | 25,384 | $13,326,600 | 0.1% |
News See All
11 Best Debt-Free Stocks to Invest in Right Now
It is widely understood that employing debt to fund operations can act as a powerful financial tool. But debt doesn't come without its trade-offs.
Regeneron's Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts.
13 Most Undervalued Large Cap Stocks to Buy According to Analysts
On July 3, Ben Preston, Portfolio Manager at Orbis Investments, appeared on CNBC to suggest that investors look past the constant political headlines and market volatility and find undervalued global ...
Regeneron Pharmaceuticals (REGN) Announces Approval of Dupixent in the US
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc.
11 Best 52-Week Low Stocks to Buy Right Now
On July 2, Tom Lee, Fundstrat's Head of Research and CIO, joined CNBC Television to discuss market conditions. He noted that the investors remain skeptical despite strong market gains.
Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.
10 Best Value Stocks to Buy According to Billionaires
The H1 2025 has been a roller coaster ride for the investors. During the initial months of the year, the benchmarks touched record highs, according to Bank of America Private Bank.
Regeneron Launches $200 Million Donation Matching Program to Support Vision Care
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential.
12 Best S&P 500 Stocks With Huge Upside Potential
Bankim Chadha, Deutsche Bank's chief global strategist, joined CNBC's 'The Exchange' on June 24 to express a cautionary view regarding further monetary policy movement despite recent positive inflation...
Billionaire Hedge Funds
